Glenmark Pharmaceuticals has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19.
The company has priced a pack of 34 tablets at Rs 3,500 (Rs 103 per tablet), the dosage is 200 mg X 9 tablets on the day one and 200 mg X 4 tablets a day for 14 days of the treatment.
Drugs Controller General of India (DCGI) gave approval to the Mumbai-based drug firm on Friday for manufacturing and marketing of FabiFlu.
FabiFlu is the first oral Favipiravir-approved medication for the treatment of COVID-19, the company said in a statement.
Favipiravir, sold under the brand name Avigan by Fujifilm Toyama Chemical and approved in Japan since 2014 in treating influenza, is already being used commercially in the therapeutic management of COVID-19 in Bangladesh and UAE.
“This approval comes at a time when cases in India are spiralling like never before, putting tremendous pressure on our healthcare system,” Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha said.
India is now the fourth worst COVID19- hit country. With nearly four lakh cases, the death has crossed the 12,500 marks.
Meantime, Bengaluru headquartered Strides Pharma Science and Bangladeshi firm Beximco are also in the race for gaining approval for their favipiravir products.